Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited announced the release of 117,697,133 fully paid ordinary shares from voluntary escrow, effective 3 February 2025. The shares were originally issued to vendors of Vaxinia Pty Ltd as approved by shareholders in 2019. This release marks a significant step in Imugene’s operational strategy, potentially impacting its market position by increasing share liquidity and stakeholder engagement.
More about Imugene Limited
Imugene Limited is a clinical stage immuno-oncology company that develops novel immunotherapies aimed at activating cancer patients’ immune systems to treat and eradicate tumors. The company leverages unique platform technologies to potentially achieve effects similar to or greater than those of synthetic monoclonal antibodies and other immunotherapies. Their pipeline includes an allogeneic cell therapy CAR T drug, azer-cel, targeting CD19 for blood cancers, multiple immunotherapy B-cell vaccine candidates, and an oncolytic virotherapy for various cancers. Imugene is supported by a team of international cancer experts and is well-funded to achieve its clinical and commercial goals.
YTD Price Performance: 35.00%
Average Trading Volume: 181,678
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $186.8M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.
